ROR1 and triple-negative breast carcinoma: Significantly, owing to the higher expression of ROR1 in NSCLC and triple-negative breast cancer ROR1 has been employed as a target of chimeric antigen receptor (CAR) T cell therapy (Srivastava et al., 2021).